#ESMO21: Proffered Paper session - Genitourinary tumours, prostate
ESMO
9/18/21, 4:30 PM
Europe/Paris GMT+2
Description
#ESMO21 Sat, 18.09.2021
Time
13:30 - 14:50 LBA24 - Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of expanded cohort 6 of the COSMIC-021 study
Presentation Number
LBA24
Speakers
Neeraj Agarwal (Salt Lake City, United States of America)
Lecture Time
13:30 - 13:40
Invited Discussant LBA24
Speakers
Cora N. Sternberg (New York, United States of America)
Lecture Time
13:40 - 13:50
Q&A and live discussion
Lecture Time
13:50 - 13:55
577O - PRINCE: Interim analysis of the phase Ib study of 177Lu-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)
Presentation Number
577O
Speakers
Shahneen K. Sandhu (Melbourne, VIC, Australia)
Lecture Time
13:55 - 14:05
Invited Discussant 577O
Speakers
Joaquin Mateo (Barcelona, Spain)
Lecture Time
14:05 - 14:15
Q&A and live discussion
Lecture Time
14:15 - 14:20
LBA25 - Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC)
Presentation Number
LBA25
Speakers
Andrew J. Armstrong (Durham, United States of America)
Lecture Time
14:20 - 14:30
Invited Discussant LBA25
Speakers
Stephane M. Oudard (Paris, France)
Previous registration necessary?
NO
YES
Simultaneous translation ?
NO
YES
Will it be recorded?
NO
YES
LBA24 - Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of expanded cohort 6 of the COSMIC-021 study, Invited Discussant LBA24, Q&A and live discussion, PRINCE: Interim analysis of the phase Ib study of 177Lu-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC), LBA25 - Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC)
Inglês
Speakers
Neeraj Agarwal, Cora N. Sternberg, Shahneen K. Sandhu, Joaquin Mateo, Andrew J. Armstrong, Stephane M. Oudard
Link to the Event
Banner to the Event
Register your event here
Already have an account? LOGIN HERE. If You don't have an account you need to create a free account.